Survodutide
Also known as · BI 456906
Overview
A once-weekly dual agonist combining GLP-1 appetite suppression with glucagon-receptor-driven energy expenditure, studied in obesity and in metabolic dysfunction-associated steatohepatitis (MASH).
Research profile · for clinicians
Based on research: an emerging incretin with published Phase 2 data in obesity and MASH. Studied for weight loss, liver-fat reduction, and fibrosis endpoints.
Mechanism of action
Balanced agonism at glucagon and GLP-1 receptors: GLP-1 signalling curbs intake while glucagon-receptor activity raises hepatic lipid oxidation and resting energy expenditure.
Research record
- [01]Phase 2 obesity trial (NEJM, 2024): ≈ 19% mean weight reduction at 46 weeks.
- [02]Phase 2 MASH trial: significant histological improvement versus placebo.
Selected references
Survodutide in adults with overweight or obesity
N. Engl. J. Med., 2024
A phase 2 trial of survodutide in MASH
N. Engl. J. Med., 2024
Research deep dive
Every cited study, explained
Plain-language walkthroughs of each reference, with direct PubMed links and dosing-literature context.